Las Vegas, Nevada, April 14, 2021 – – CECORS, INC. (OTC PINK: CEOS) (“CeCors” or the “Company”), is pleased to announce that its wholly-owned Canadian subsidiary PsyKey Inc. has entered into a letter of intent with MycoVita Canada Inc. (“MycoVita”) to form a strategic partnership. The PsyKey – MycoVita strategic partnership will focus on the research, development, and commercialization of Mycology based formulations, products, and therapeutics, including exploring scientific and research-based approaches in regards to psilocybin and its uses as a potential therapeutic.
MycoVita, whose name is derived from Latin meaning “mushroom life” is a Biotech company focused on the development of functional foods and products that support optimal health and wellbeing through science backed formulations and research. Mushrooms and their derived bio-products offer unique benefits for both the body and mind, ranging from immune support, cognition and memory enhancement, to energy and stamina boost. MycoVita is targeting these areas to deliver measurable results for healthy outcomes.
MycoVita was founded by Dr. Omon Isikhuemhen who is currently a leading mushroom science and fungal biotechnology professor at the North Carolina A&T State University. Dr. Isikhuemhen credentials include a Bachelor of Science with honors, a Masters of Science in Botany, as well as a Ph.D in Microbiology. Dr. Isikhuemhen is a trail blazer in research and development that has resulted in many technological advancements, products, and numerous scientific publications.
“The synergies of the PsyKey – MycoVita strategic partnership are truly exciting. Having the opportunity to partner with a company founded by a world class mycologist, whose goals and ambitions align with those of ours, will provide us with significant advantages as we continue to execute our growth and expansion strategy in the fast-evolving market for mycology based products and therapeutics,” said Amar Bhatal, president of CeCors Inc. “We look forward to announcing more about our exciting planned products and additional business developments in the near future.”
For further information:
Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency, and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward- looking statements.